Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons

Clinical Biochemistry

Volumn 40, Issue 13-14, 2007, Pages 964-968

  Vogeser, Michael ^a   König, Daniel ^b   Frey, Ingrid ^b   Predel, Hans Georg ^c   Parhofer, Klaus Georg ^a   Berg, Aloys ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Center of Internal Medicine   (Germany)

^c GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

HOMA IR; Insulin resistance; Lifestyle intervention; Obesity

Indexed keywords

CARBOHYDRATE; GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE; LIFESTYLE MODIFICATION; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; MALE; MIDDLE AGED; OBESITY;

EID: 34548118598     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.05.009     Document Type: Article

References (36)

1. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol. Metab. Clin. N. Am. 33 (2004) 283-303
2. Stoll B.A. Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur. J. Clin. Nutr. 53 (1999) 83-87
3. Abbasi F., Brown Jr. B.W., Lamendola C., McLaughlin T., and Reaven G.M. Relationship between obesity, insulin resistance, and coronary heart disease risk. J. Am. Coll. Cardiol. 40 (2002) 937-943
4. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
5. de Simone G., Devereux R.B., Palmieri V., Roman M.J., Celentano A., Welty T.K., et al. Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study. Nutr. Metab. Cardiovasc. Dis. 13 (2003) 140-147
6. Malik S., Wong N.D., Franklin S.S., Kamath T.V., Lltalien G.J., Pio J.R., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
7. Rowers M., Zaccaro D., D'Agostino R., Haffner S., Saad M.F., Selby J.V., et al. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27 (2004) 781-787
8. Saad M.F., Rewers M., Selby J., Howard G., Jinagouda S., Fahmi S., et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension 43 (2004) 1324-1331
9. Saely C.H., Aczel S., Marte T., Langer P., Hoefle G., and Drrexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J. Clin. Endocrinol. Metab. 90 (2005) 5698-5703
10. Yip J., Facchini F.S., and Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab. 83 (1998) 2773-2776
11. Brochu M., Tchernof A., Dionne I.J., Sites C.K., Eltabba G.H., Sims E.A., et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?. J. Clin. Endocrinol. Metab. 86 (2001) 1020-1025
12. Karelis A.D., St-Pierre D.H., Conus F., Rabasa-Lhoret R., and Poehlman E.T. Metabolic and body composition factors in subgroups of obesity: what do we know?. J. Clin. Endocrinol. Metab. 89 (2004) 2569-2575
13. McLaughlin T., Allison G., Abbasi F., Lamendola C., and Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 53 (2004) 495-499
14. Berg A., and König D. Aspects of prevention and therapy of lipid metabolism disorders especially in considering the metabolic syndrome. Dtsch. Z. Sportmed. 56 (2005) 74-82
15. Calle E.E., Teras L.R., and Thun M.J. Obesity and mortality. N. Engl. J. Med. 353 (2005) 2197-2199
16. Flegal K.M., Graubard B.I., Williamson D.F., and Gail M.H. Excess deaths associated with underweight, overweight, and obesity. JAMA 293 (2005) 1861-1867
17. Facchini F.S., Hua N., Abbasi F., and Reaven G.M. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 86 (2001) 3574-3578
18. Nilsson P., Nilsson J.A., Hedblad B., Eriksson K.F., and Berglund G. Hyperinsulinaemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmo Preventive Project. J. Intern. Med. 253 (2003) 136-145
19. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
20. Haffner S.M., Gonzalez C., Miettinen H., Kennedy E., and Stern M.P. A prospective analysis or the HOMA model: The Mexico City Diabetes Study. Diabetes Care 19 (1996) 1138-1141
21. Yeni-Komshian H., Carantoni M., Abbasi F., and Reaven G.M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 23 (2000) 171-175
22. McAuley K.A., Williams S.M., Mann J.I., Walker R.J., Lewis-Barned N.J., Temple L.A., et al. Diagnosing insulin resistance in the general population. Diabetes Care 24 (2001) 460-464
23. Ascaso J.F., Pardo S., Real J.T., Lorente R.I., Priego A., and Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26 (2003) 3320-3325
24. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 139 (2003) 802-809
25. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
26. McLaughlin T., Reaven G., Abbasi F., Lamendola C., Saad M., Waters D., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am. J. Cardiol. 96 (2005) 399-404
27. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000) 57-63
28. Tuan C.-Y., Abbasi F., Lamendola C., McLaughlin T., and Reaven G. Usefulness of plasma glucose and insulin concentrations in identifying patients with insulin resistance. Am. J. Cardiol. 92 (2003) 606-610
29. Vaccaro O., Masulli M., Cuomo V., Rivellese A.A., Luusitupa M., Vessby B., et al. Comparative evaluation of simple indices of insulin resistance. Metabolism 53 (2004) 1522-1526
30. Stern S.E., Williams K., Ferrannini E., DeFronzo R.A., Bogardus C., and Stern M.P. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54 (2005) 333-339
31. Vogeser M., and Parhofer K.G. Limited preanalytical requirements for insulin measurement. Clin. Biochem. 38 (2005) 572-575
32. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289 (2003) 1799-1804
33. Monzillo L.U., Hamdy O., Horton E.S., Ledbury S., Mulooly C., Jarema C., et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes. Res. 11 (2003) 1048-1054
34. Park H.S., and Lee K. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity. Diabet. Med. 22 (2005) 266-272
35. Wadden T.A., Berkowits R.I., Womble L.G., Sarwer D.B., Phelan S.R., Cato K., et al. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. N. Engl. J. Med. 353 (2005) 2111-2120
36. Despés J.P. Is visceral obesity the cause of the metabolic syndrome?. Ann. Med. 38 (2006) 52-63